查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1733328

全球医疗奈米技术（奈米医学）市场规模（按模式、适应症、应用、区域范围和预测）

Global Healthcare Nanotechnology (Nanomedicine) Market Size By Modality (Treatment, Diagnostics), By Indication (Clinical oncology, Infectious diseases), By Application (Drug Delivery, Regenerative medicine), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

医疗奈米技术（奈米医学）市场规模与预测

2024 年医疗奈米技术（奈米医学）市场规模价值 2,203.4 亿美元，预计到 2032 年将达到 5,529.3 亿美元，2026 年至 2032 年的复合年增长率为 13.14%。

随着法律规范的完善，全球医疗奈米技术（奈米医学）市场正在成长。开创性的技术发展和不断增加的研究投入将推动市场扩张。 COVID-19 对奈米医学领域产生了相对正面的影响。这是因为奈米药物在治疗癌症类疾病的需求迅速成长。此外，由于各领域的奈米医学研发活动的活性化，市场参与企业在材料和资源方面的支出也在增加。全球医疗奈米技术（奈米医学）市场报告对市场进行了全面评估。它对关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

定义全球医疗奈米技术（奈米医学）市场

奈米技术是21世纪最有前途的技术之一。奈米技术是指技术发展发生在 0.1 至 100 奈米尺度上时所使用的术语。奈米医学通常是奈米技术的一个分支，涉及分子层面的医学发展，用于疾病的诊断、预防、治疗，甚至组织和器官的再生。奈米技术是21世纪最有前途的技术之一。奈米技术是指技术发展发生在 0.1 至 100 奈米尺度上时所使用的术语。奈米医学通常是奈米技术的一个分支，涉及在分子层面上开发医学治疗方法，以诊断、预防、治疗疾病，甚至组织和器官的再生。

维持和改善人类健康是帮助实现这一目标的一种方式。奈米医学为各种危及生命的疾病提供了强有力的解决方案，例如整形外科问题、血液、肺部、癌症、帕金森氏阿兹海默症、阿兹海默症、糖尿病以及与神经和循环系统相关的疾病。这些是具有可程式设计特性的多功能药物，将有助于利用奈米设备和奈米粒子在分子层面监测、建构、修復和控制生物系统。它由多种技术支持，包括树状聚合物、胶束、结晶、富勒烯、病毒体奈米颗粒、奈米孔、脂质体、奈米棒、乳化、量子点和奈米机器人。

奈米医学可能是治疗癌症的一种有希望的途径。这一日益增长的医学研究领域通常是由寻找针对各种疾病（包括癌症）的更个人化的治疗方法的愿望所驱动。奈米医学的优点在于拥有奈米级材料的特性，因此有望开发出比标准治疗方法更有效、副作用更少的创新药物。因此，对技术进步的需求以增强疾病的诊断、治疗和预防已被证明是医疗奈米技术（奈米医学）市场的主要驱动力。就癌症而言，奈米医学为目前的癌症诊断和治疗方法带来了有希望的转变。

全球医疗奈米技术（奈米医学）市场概览

奈米医学有可能彻底改变和革新当前疾病的检测、诊断和治疗方式。随着药物传输等创新技术的出现，奈米医学提供了多种优势，预计将显着推动全球医疗奈米技术（奈米医学）市场的发展。政府资金和支持的增加将导致市场需求增加，而安全且具有成本效益的治疗方法将支持市场成长。

新兴经济体中奈米药物许可的增加和医疗设施的成长有助于为市场成长创造充足的机会。预计与疾病早期诊断、预防干预以及慢性和急性疾病预防相关的应用等技术进步将推动该市场的成长。奈米技术透过在奈米尺度上将较大的结构和化学物质微型化，正在迅速彻底改变药物输送，从而影响该技术的采用。

由于政府机构的资金增加，奈米机器人技术有望发展，这将激发市场潜力。预计由奈米分子和相关技术驱动的产品线将为市场带来潜在的成长途径。 DNA摺纸在医疗保健应用中的使用将推动全球医疗保健奈米技术（奈米医学）市场的成长。然而，漫长的核准过程和与奈米医学相关的风险（环境影响）限制了市场的成长。

目录

第一章 全球医疗奈米技术（奈米医学）市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章 全球医疗奈米技术（奈米医学）市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球医疗保健领域奈米技术（奈米医学）市场（按方式）

  • 概述
  • 治疗
  • 诊断

第六章 全球医疗奈米技术（奈米医学）市场（按适应症）

  • 概述
  • 临床肿瘤学
  • 感染疾病
  • 临床心臟病学
  • 整形外科
  • 神经病学
  • 泌尿系统
  • 眼科
  • 免疫学
  • 其他的

7. 全球医疗奈米技术（奈米医学）市场（按应用）

  • 概述
  • 药物输送
  • 再生医学
  • 植入
  • 诊断
  • 影像学
  • 疫苗
  • 其他的

8. 全球医疗奈米技术（奈米医学）市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

9. 全球医疗奈米技术（奈米医学）市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第十章 公司简介

  • Sanofi SA
  • Abbott
  • Pfizer Inc.
  • CombiMatrix Corporation
  • GE Healthcare
  • Celgene Corporation
  • Johnson & Johnson Services, Inc.
  • Luminex Corporation
  • Merck & Company, Inc.
  • Nanosphere
  • Nanosphere, Inc.
  • Bristol-Myers Squibb
  • Leadient BioSciences Inc.
  • Teva Pharmaceutical Industries Ltd
  • Mallinckrodt plc.

第十一章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十二章 附录

  • 相关调查
简介目录
Product Code: 63885

Healthcare Nanotechnology (Nanomedicine) Market Size And Forecast

Healthcare Nanotechnology (Nanomedicine) Market size was valued at USD 220.34 Billion in 2024 and is projected to reach USD 552.93 Billion by 2032, growing at a CAGR of 13.14% from 2026 to 2032.

The Global Healthcare Nanotechnology (Nanomedicine) Market is growing as the regulatory framework improves. Growth in technological developments, as well as an increase in research investment, will drive market expansion. COVID-19 has had a relatively good impact on the nanomedicine sector. This was attributable to a surge in the need for nanomedicines used to treat cancer-like disorders. Furthermore, market participants have seen a growth in spending on materials and resources as a result of an increase in nanomedicine R&D activities in all areas. The Global Healthcare Nanotechnology (Nanomedicine) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Healthcare Nanotechnology (Nanomedicine) Market Definition

Nanotechnology is one of the foremost promising technologies in the 21st century. Nanotechnology may be a term used when technological developments occur at a 0.1 to 100 nm scale. Nanomedicine is usually a branch of nanotechnology as it involves medicine development at a molecular scale for diagnosis, prevention, treatment of diseases, and even regeneration of tissues and organs. Nanotechnology is one of the foremost promising technologies in the 21st century. Nanotechnology may be a term used when technological developments occur at a 0.1 to 100 nm scale. Nanomedicine is usually a branch of nanotechnology as it involves medicine development at a molecular scale for diagnosis, prevention, treatment of diseases, and even regeneration of tissues and organs.

Preserving and improving human health helps in doing so. For various life-threatening diseases like orthopedic problems, diseases related to blood, lungs, cancer, Parkinson's, Alzheimer's, diabetes, neurological, and cardiovascular system Nanomedicine offers a strong solution. These are multifunctional drugs with programmable properties which help in finding the applications such as monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. Development of a replacement nanomedicine takes several years which is supported by various technologies like dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

Nanomedicine may be a promising mode of cancer treatment. This growing field of medical research is often wont to discover a better-personalized treatment for a good range of diseases, including cancer. As nanomedicine promises to develop innovative drugs which have greater efficacy and lesser side effects than standard therapies because of its benefits as it has the properties of matter at the nanoscale. The necessity for technological advancements to reinforce disease diagnosis, treatment, and prevention is thus found to be the main driver for the Healthcare Nanotechnology (Nanomedicine) Market. Within the case of cancers, nanomedicine offers promising changes from the present methods of diagnosing and treating cancer.

Global Healthcare Nanotechnology (Nanomedicine) Market Overview

Nanomedicines have the potential which can fully change or revolutionalize the current scenario of detection of disease, diagnosis, and treatment methods. With the emergence of innovative technologies such as drug delivery, and also there are several benefits of nanomedicine that will significantly boost the Global Healthcare Nanotechnology (Nanomedicine) Market. Rising government funding and support will lead to an increase in demand for the market as well as its safe and cost-effective therapies will support the market growth.

The increasing out-licensing of nano drugs and the growth of healthcare facilities in emerging economies help in creating an ample amount of opportunities for market growth. Technological advancements including relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic also as acute disorders are expected to bolster growth in this market. Nanotechnology involves The miniaturization of larger structures and chemicals at a nanometric scale involves Nanotechnology rapidly revolutionized drug administration, thus influencing the adoption of the technology.

Expected developments in nanorobotics due to the increase in funding from the govt organizations are expected to induce potential in the market. The potential pipeline of products supported by the nano molecules and associated technologies is anticipated to drive the market with potential avenues of growth. Utilization of DNA origami for healthcare applications driving the growth of the Global Healthcare Nanotechnology (Nanomedicine) Market. However, the long approval process and risks related to nanomedicine (environmental impacts) restrain the market growth.

Global Healthcare Nanotechnology (Nanomedicine) Market Segmentation Analysis

The Global Healthcare Nanotechnology (Nanomedicine) Market is segmented on the basis of Modality, Indication, Application, And Geography.

Healthcare Nanotechnology (Nanomedicine) Market, By Modality

  • Treatment
  • Diagnostics

Based on Disease, The market is bifurcated into Treatment and Diagnostics. The Treatment segment holds the largest market share among the others and is anticipated to stay dominant during the projected timeline, owing to technological breakthroughs in nanomedicines, increased nanomedicine adoption, rising chronic disease incidence rates, and an increase in the number of advanced and effective product launches.

Healthcare Nanotechnology (Nanomedicine) Market, By Indication

  • Clinical oncology
  • Infectious diseases
  • Clinical cardiology
  • Orthopedics
  • Neurology
  • Urology
  • Ophthalmology
  • Immunology
  • Others

Based on Application, The market is bifurcated into Clinical oncology, Infectious diseases, Clinical cardiology, Orthopedics, Neurology, Urology, Ophthalmology, Immunology, and Others. The Clinical oncology category was the largest category contributing to the growing market and is expected to maintain its dominance during the projected timeline, owing to an increase in the number of oncology disorders and rising disposable income. In the subject of oncology, nanomedicine provides intriguing alternatives to current cancer treatment and diagnosis approaches. The use of nano-based cancer medicines and diagnostics has made significant progress, and numerous new breakthroughs are currently in the works. Nanobiotix, a clinical-stage nanomedicine company, received CE approval in April 2019 for Hensify (NBTXR3), which is an aqueous suspension of crystalline hafnium oxide or HfO2 nanoparticles intended for injection directly into the tumor prior to a patient's first classic radiation therapy treatment of advanced soft tissue sarcoma.

Healthcare Nanotechnology (Nanomedicine) Market, By Application

  • Drug delivery
  • Regenerative medicine
  • Implants
  • Diagnostic
  • Imaging
  • Vaccines
  • Others

Based on Application, The market is bifurcated into Drug Delivery, Regenerative medicine, Implants, Diagnostic, Imaging, Vaccines, and Others. The Drug delivery sector was the largest contributor to the international market and is expected to persist dominant throughout the projected period, owing to a rise in the frequency of diseases like cancer and the COVID-19 virus, as well as a rise in awareness of the applications of nanomedicines.

Healthcare Nanotechnology (Nanomedicine) Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
  • On the basis of Regional Analysis, The Global Healthcare Nanotechnology (Nanomedicine) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounts for the maximum market share in this segment. The primary drivers driving market growth in the United States include technology improvements along with applicable applications in early illness detection, preventative intervention, and prevention of chronic and acute disorders, which are likely to drive market expansion. According to the CDC, heart disease accounted for one in every four fatalities in the United States in 2021. Coronary heart disease is the largest cause of death due to cardiac disease in the United States, accounting for 360,900 fatalities, and is followed by stroke (805,000). This high burden may result in a large need for particular therapeutic nano vectors, nanostructured stents, and tissue regeneration implants.
  • Furthermore, various R&D efforts on nanotechnology-based medications and diagnostics are underway in the country, which may fuel market expansion. For instance, in January 2020, Stanford University researchers produced a medication coated with nanoparticles that slows the progression of atherosclerosis in rats by lowering plaque deposition in their arteries without generating negative side effects. However, Asia-Pacific is predicted to develop at the fastest rate over the forecast period. Furthermore, Japan and China are projected to grow at a rapid CAGR in the Asia-Pacific nanomedicine market, owing to improvements in healthcare infrastructure, an increase in the number of health facilities coupled with smart instruments, the development of the R&D sector, an increase in healthcare reforms, and adoption of advanced technologies of nanomedicines.

Key Players

The "Global Healthcare Nanotechnology (Nanomedicine) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Sanofi SA, Abbott, Pfizer Inc., CombiMatrix Corporation, GE Healthcare, Celgene Corporation, Johnson & Johnson Services, Inc., Luminex Corporation, Merck & Company, Inc., Nanosphere, Inc., Bristol-Myers Squibb, Leadient BioSciences Inc., Teva Pharmaceutical Industries Ltd, Mallinckrodt plc. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • January 2022 - NaNotics LLC has formed a research partnership with the Mayo Clinic to create a NaNot which addresses the soluble form of PD-LI, a tumor-generated immunological inhibitor.
  • December 2021 - Acura NanoMedicine Inc has announced the development of a nanotechnology-based approach to reduce medication resistance and revitalize cancer treatments.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY MODALITY

  • 5.1 Overview
  • 5.2 Treatment
  • 5.3 Diagnostics

6 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY INDICATION

  • 6.1 Overview
  • 6.2 Clinical oncology
  • 6.3 Infectious diseases
  • 6.4 Clinical cardiology
  • 6.5 Orthopedics
  • 6.6 Neurology
  • 6.7 Urology
  • 6.8 Ophthalmology
  • 6.9 Immunology
  • 6.10 Others

7 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY APPLICATION

  • 7.1 Overview
  • 7.2 Drug delivery
  • 7.3 Regenerative medicine
  • 7.4 Implants
  • 7.5 Diagnostic
  • 7.6 Imaging
  • 7.7 Vaccines
  • 7.8 Others

8 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Sanofi SA
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Abbott
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Pfizer Inc.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 CombiMatrix Corporation
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 GE Healthcare
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Celgene Corporation
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Johnson & Johnson Services, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Luminex Corporation
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Merck & Company, Inc.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Nanosphere
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments
  • 10.11 Nanosphere, Inc.
    • 10.11.1 Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Outlook
    • 10.11.4 Key Developments
  • 10.12 Bristol-Myers Squibb
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments
  • 10.12 Leadient BioSciences Inc.
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments
  • 10.13 Teva Pharmaceutical Industries Ltd
    • 10.13.1 Overview
    • 10.13.2 Financial Performance
    • 10.13.3 Product Outlook
    • 10.13.4 Key Developments
  • 10.14 Mallinckrodt plc.
    • 10.14.1 Overview
    • 10.14.2 Financial Performance
    • 10.14.3 Product Outlook
    • 10.14.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research